Business, energy, technology, markets and global industry news from Business News Today

BRIXADI

PharmaDeviceNews BRIXADI
Representative image of a clinician preparing an injectable treatment in an outpatient care setting, illustrating Braeburn’s latest BRIXADI data on long-acting buprenorphine, opioid withdrawal suppression, and treatment retention in opioid use disorder.
Pharma & Biotech

Braeburn’s BRIXADI evidence package raises new questions for injectable buprenorphine adoption

Braeburn’s new BRIXADI data shows retention and dosing signals in opioid use disorder. Find out what it means for treatment strategy.

Read More